Drug intelligence / Profile preview

anti-CD19 IL10 CAR-NK

Development stage: Preclinical
Lead developer: Second Affiliated Hospital of Zhejiang University School of Medicine
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Anti-CD19 IL10 CAR-NK is a cellular immunotherapy that uses natural killer (NK) cells engineered with a chimeric antigen receptor (CAR) targeting CD19, a surface protein found on B cells, combined with interleukin-10 (IL-10). This therapy represents part of the next generation of cellular immunotherapies that aim to overcome limitations of CAR-T cell therapies. CAR-NK cells have shown promising results in preclinical and early clinical studies for treating various B-cell malignancies, with potentially fewer side effects than CAR-T therapies.

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on anti-CD19 IL10 CAR-NK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CD19 IL10 CAR-NK.

Explore the full profile